Renal replacement therapy: summary of NICE guidanceBMJ 2018; 363 doi: https://doi.org/10.1136/bmj.k4303 (Published 19 October 2018) Cite this as: BMJ 2018;363:k4303
All rapid responses
Rapid responses are electronic comments to the editor. They enable our users to debate issues raised in articles published on bmj.com. A rapid response is first posted online. If you need the URL (web address) of an individual response, simply click on the response headline and copy the URL from the browser window. A proportion of responses will, after editing, be published online and in the print journal as letters, which are indexed in PubMed. Rapid responses are not indexed in PubMed and they are not journal articles. The BMJ reserves the right to remove responses which are being wilfully misrepresented as published articles or when it is brought to our attention that a response spreads misinformation.
From March 2022, the word limit for rapid responses will be 600 words not including references and author details. We will no longer post responses that exceed this limit.
The word limit for letters selected from posted responses remains 300 words.
It's striking that the UK has half the incidence of end-stage renal disease than the US. I'm also impressed that the majority of the UK's ESRD patients are transplanted which I agree is the best treatment for ESRD. Prevention, of course, would be even better. What the article failed to reference is that 90% of dialysis has been preventable since 2002 (1). If that were known (2), there would be no waiting list at all for a cadaver kidney transplant in either the UK or the US. There would be no need for living donors, and both countries could be dialysis-free within 5 years.
In acute renal therapy, it's also possible to avoid renal replacement therapy (RRT) (3).
1. Paper #1 at www.genomed.com/publications (abstract at PubMed ID: 12396747)
2. Paper #9 at www.genomed.com/publications
Competing interests: I am the Founder, CEO, and majority shareholder of GenoMed, Inc, a NextGen Disease Management company that uses genomics to solve diseases. We use knowledge of disease-causing genes to improve prediction and treatment of common diseases like kidney failure. We repurpose already existing drugs whenever possible.